Announcements Trials
Browse Landscape

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 8Observational 2

Sponsor

Conditions

Myasthenia Gravis 2Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1

Interventions

ravulizumab 3Tacrolimus 3Pyridostigmine Bromide 3Prednisone 3Mycophenolic Acid 3Data Collection 3Azathioprine 3efgartigimod alfa 2Steroids 2Diagnostic Self Evaluation 2Blood Specimen Collection 2rozanolixizumab 1Thymectomy 1Therapeutics 1Telemedicine 1Neurofeedback 1Methylprednisolone 1Methotrexate 1Immunosuppressive Agents 1Immunoglobulins, Intravenous 1Genotype 1Cyclosporine 1Cyclophosphamide 1Biomarkers 1Alleles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Myasthenia Gravis × efgartigimod alfa × Clear all
NCT06298565 2026-02-17

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

argenx

Recruiting
680 enrolled

Myasthenia Gravis

NCT06299748 2026-02-17

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

argenx

Recruiting
279 enrolled

Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡